Giorgi-Pierfranceschi M, Núñez JJL, Monreal M, et al. - Among patients with venous thromboembolism (VTE), a comparison was performed between those with morbid obesity (body mass index [BMI] ≥ 40) vs those with normal weight (BMI: 18.5-24.9), focusing on mortality risk during anticoagulation in this study utilizing data from RIETE registry. Separate analyses of those with or without active cancer were performed. The RIETE included 4,443 VTE patients with morbid obesity and 12,047 having a normal weight, by September 2018. Among those, cancer was detected in 245 (5.5%) and 1,397 (11.6%) respectively. The longer median duration of anticoagulant treatment was reported in the morbidly obese, with- (185 vs 114 days) or without cancer (203 vs 177 days). Findings revealed approximately one third lower risk for mortality during anticoagulation in VTE patients who were morbidly obese vs those with normal weight, independently of the presence of cancer.